Back to Search
Start Over
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
- Source :
- Expert Review of Hematology, 13(4), 421-433. Taylor & Francis Ltd
- Publication Year :
- 2020
-
Abstract
- Lack of head-to-head trials highlights a need for comparative real-world evidence of proteasome inhibitors plus Rd. Methods: In this retrospective, US population-representative EHR study of RRMM patients initiating IRd, KRd, or VRd in line of therapy (LOT) ≥2 between 1/2014 and 9/30/2018, 664 patients were treated in LOT ≥2 with: IRd, n = 168; KRd, n = 208; VRd, n = 357. Median age was 71/65/71 years; 67%/70%/75% had a frailtymodified score of intermediate/frail; 20%/28%/13% had high cytogenetic risk in I-/K-/V-Rd groups. Risk of PI-triplet discontinuation was lower for I- vs. K-Rd (HR: 0.71) and I- vs. V-Rd (HR: 0.85); unadjusted, median TTNTs (months): 12.7/8.6/14.2 (LOT ≥2) and 16.8/9.5/14.6 (LOT 2–3) (I-/K-/V-Rd). Adjusted TTNT was comparable between I-/K-/V-Rd in LOT ≥2 with a TTNT benefit among intermediate/frail patients for I- (HR: 0.70; P=0.04) and V- (HR: 0.73; P50% of patients are excluded. Individualized treatment based on patient characteristics, such as frailty status, is especially pertinent in an elderly RRMM population.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Disease-Free Survival
Ixazomib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Aged
Retrospective Studies
Bortezomib
business.industry
Real world outcomes
Refractory Multiple Myeloma
Hematology
Middle Aged
Carfilzomib
Survival Rate
body regions
chemistry
030220 oncology & carcinogenesis
Female
Multiple Myeloma
business
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 17474086
- Volume :
- 13
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Expert Review of Hematology
- Accession number :
- edsair.doi.dedup.....1474a0ec9f6076c282bc6f64b7d364e6